A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial.

Simon Gampenrieder (Speaker), A Risch, G Rinnerthaler, H Hackl, M. Steiner, Walter Pulverer, Andreas Weinhäusel, Suzana Ilic, Clemens Hufnagl, Cornelia Hauser-Kronberger, A Egle, R. Greil

Research output: Poster presentation without proceedingspeer-review

Original languageEnglish
Publication statusPublished - 2018
EventSan Antonio Breast Cancer Symposium 2018 -
Duration: 4 Dec 20188 Dec 2018

Conference

ConferenceSan Antonio Breast Cancer Symposium 2018
Period4/12/188/12/18

Research Field

  • Molecular Diagnostics

Cite this